Targeting therapeutic gene expression to tumor cells represents a major challenge for cancer gene therapy. The strong transcriptional response exhibited by heat shock genes, along with the beneficial therapeutic effects of hyperthermia have led us to develop a heatdirected gene -targeting strategy for cancer treatment. Heat shock gene expression is mediated in large part by the interaction of heat shock factor 1 with specific binding sites ( heat shock elements; HSE ) found in the promoters of heat -inducible genes. Here we present a quantitative analysis of heat -inducible gene expression mediated by the wild -type hsp70b gene promoter, as well as a modified hsp70b promoter containing additional HSE sequences. -Galactosidase ( -gal ) expression was induced between 50 -and 800 -fold in a panel of human breast cancer cell lines infected with an adenoviral vector containing the wild -type hsp70b promoter ( Ad.70b.g ) following treatment at 438C for 30 minutes. Infection with an adenoviral vector containing the modified hsp70b promoter ( Ad.HSE.70b.g ) resulted in a 200 -to 950 -fold increase in -gal expression under the same conditions, and also provided a 1 ± 28C decrease in the threshold of activation. Significant increases in the heat responsiveness of the Ad.HSE.70b.g construct were observed in five of six tumor cell lines tested, as well as under thermotolerant conditions. Finally, we demonstrate that localized heating of a HeLa cell xenograft can effectively target -gal gene expression following intratumoral injection of Ad.70b.g. Adenoviral vectors incorporating heat -inducible therapeutic genes may provide useful adjuncts for clinical hyperthermia. Cancer Gene Therapy ( 2000 ) 7, 1566 ± 1574
G ene therapy has the potential to have a significant impact on cancer treatment. However, the inability of current gene transfer vectors to target tumor cells directly limits the usefulness of this approach due to normal tissue toxicity. One solution to this problem is to utilize genes that are less toxic but can sensitize tumor cells to existing antineoplastic modalities. For example, the synergistic effect of wild -type p53 gene transfer combined with radiation treatment has already been established in preclinical studies, 1 and similar strategies are currently being evaluated in clinical trials. 2 A second solution is to specifically target the expression of therapeutic genes to tumor cells. A number of tissue -or tumor-specific promoters have already been tested in a variety of models with promising results. These include the -fetoprotein promoter in hepatocellular carcinoma, 3 the tyrosinase promoter in melanoma, 4 the CEA promoter in CEA positive lung carcinoma, 5 and the stressinducible grp78 /BiP promoter in fibrosarcoma. 6 An alternative strategy is to use existing antineoplastic modalities to target gene expression to the tumor volume. For example, radiation -responsive promoters that provide a 3 -to 4 -fold induction in gene expression have been used successfully in preclinical studies to enhance the effects of radiation by simultaneously driving the expression of a toxic gene in the radiation field. 7, 8 Our laboratory is interested in examining the possibility of targeting therapeutic gene expression to tumor cells using a heat -inducible gene transfer vector.
Hyperthermia uses a variety of techniques (e.g., ultrasound, radio frequency or microwave radiation ) to raise the temperature of a localized tumor, typically by 5 ±78C. In preclinical studies, hyperthermia was shown to act as a sensitizing agent for radiation and chemotherapy. 9 Several randomized clinical trials have shown that the combination of hyperthermia and radiation therapy achieves a superior response rate over radiation alone in a number of tumor sites, including breast carcinoma. 10 Widespread acceptance of hyperthermia as a standard cancer treatment has been hampered, however, by difficulties in achieving a homogeneous temperature dose throughout the target tumor. Temperature inhomogeneity has been shown to impact on outcome and this is due to technical challenges as well as the heat -sink effects caused by the tumor vasculature.
The temperatures reached in hyperthermia treatment activate the heat shock response in cells. Certain members of the heat shock gene family are quiescent in resting cells but strongly induced following heat damage. This expression of heat shock proteins allows cells to repair damage and provides transient protection from further heat stress, a phenomenon known as thermotolerance. Heat shock gene expression is mediated in large part at the transcriptional level through the interaction of activated trimers of heat shock factor 1 (HSF -1 ) with specific DNA sequences known as heat shock elements ( HSE ) found in the promoters of heat -inducible genes. 13 Incorporation of a heat shock gene promoter into a gene transfer vector has the potential to provide a high level of control over therapeutic gene expression in a locally heated tumor.
We propose that limitations associated with temperature inhomogeneity and normal tissue toxicity can be addressed by combining hyperthermia treatment with a heat -inducible gene transfer vector. Heat -directed expression of a therapeutic gene with a substantial bystander effect 14, 15 could significantly enhance the therapeutic benefit of hyperthermia although at the same time limit nonspecific expression in other tissues. This concept has been demonstrated through heat -inducible expression of cytosine deaminase and thymidine kinase genes in prostate cancer cells. 16 Recently, heat -directed targeting of GFP 17, 18 and therapeutic genes such as interleukin -2, 19 interleukin -12, and tumor necrosis factor 18 has shown good success in glioma and melanoma tumor models. Further evaluation of the clinical utility of this approach will require a detailed characterization of the expression of heat -inducible promoters in the context of specific gene transfer vectors and target tumor cells. Our laboratory is interested in developing a heat -directed genetargeting strategy for breast and cervical cancers using adenoviral vectors. In this study, we describe the construction and characterization of recombinant adenoviral vectors in which the expression of a -galactosidase ( -gal ) reporter gene is under the control of either the wild -type human hsp70b promoter or a modified hsp70b promoter to which extra HSE sequences have been appended. The results demonstrate that the hsp70b promoter exhibits low levels of basal activity in the context of an adenoviral vector, and can be induced significantly in response to heat treatment of human breast and cervical cancer models in vitro and in vivo. Furthermore, the addition of HSE sequences was seen to increase gene expression in both heated and thermotolerant cells.
MATERIALS AND METHODS

Cell lines and hyperthermia
MCF -7, MDA -MB -468 ( ATCC ) and 293 cells (Microbix, Toronto, Ontario, Canada ) were maintained in -minimal essential medium ( -MEM ) containing 10% vol /vol fetal bovine serum (FBS ). BT-20 cells (ATCC ) were also maintained in -MEM but supplemented with 20% FBS. SK.Br-3 cells (ATCC ) were maintained in McCoy's ( 5A ) medium plus 10% FBS. T47D cells (ATCC ) were cultured in RPMI 1640 medium plus 10% FBS. MDA -MB -231 cells ( ATCC ) were grown in Leibowitz (L15 ) medium plus 10% FBS. The culture medium was supplemented with 100 U / mL penicillin and 100 g /mL streptomycin and cells were grown at 378C in 5% CO 2 . Experiments were conducted using monolayers of cells at 70 ±80% confluency. For hyperthermia experiments, flasks (Nunc, Rosilde, Denmark ) were sealed and cells heat shocked by immersion in a calibrated water bath (Grant Inst., Cambridge, UK ). The desired temperature was maintained at 0.058C for the time stipulated. Following heating, flasks were immediately returned to the 378C incubator under the conditions described above. Figure 1 depicts the adenoviral constructs schematically. Briefly, a nuclear localizing form of the Escherichia coli -gal gene flanked 3 H by SV40 polyadenylation sequences was cloned into the adenoviral shuttle vector pÁE1sp1A ( Microbix ) as a HindIII / BamHI fragment (designated pNLS -gal /sp1A ). A 461-bp BamHI /HindIII fragment of the human hsp70b gene promoter containing most of the 5 H untranslated region ( À 352 to +114 bp ) was subcloned from plasmid pSPV-120 ( Stressgen, Victoria, British Columbia, Canada ) into the adenoviral shuttle vector pÁE1sp1B. Subsequently, the promoter was excised from this plasmid as a BglII /SalI fragment and subcloned Figure 1 . Schematic representation of recombinant adenoviruses Ad.70b.g and Ad.HSE.70b.g. Recombinant adenoviruses containing either the wild -type hsp70b promoter ( Ad.70b.g ) or the HSEmodified promoter ( Ad.HSE.70b.g ) were generated by homologous recombination in 293 cells as described in Materials and Methods. Ad.70b.g contains a nuclear localizing form of the E. coligalactosidase gene ( NLS -LacZ ) flanked 3
Adenoviral vector construction
H by SV40 polyadenylation sequences cloned downstream of a 461 -bp fragment corresponding to the human hsp70b gene promoter ( Hsp70b ). Ad.HSE.70b.g is identical to Ad.70b.g except that it contains an additional 65 bp of sequence corresponding to three consensus binding sequences for the heat shock transcription factor 1 ( HSF -1 ) cloned upstream of the hsp70b promoter ( HSEÂ3 ). Expression cassettes substitute for deleted sequences in the E1 region of the adenoviral genome ( nucleotides 342 ± 3523 ) and are oriented in the opposite direction relative to wild -type E1 gene transcription. 21 The plasmid bearing the modified promoter was dubbed pHSE70bg.
Recombinant replication-defective ( E1/ E3 deleted ) adenoviruses ( Ad.70b.g and Ad.HSE.70b.g ) were generated by homologous recombination of the aforementioned shuttle vectors with the E1 / E3 deleted adenoviral genomic plasmid pJM17 (Microbix ) by cotransfection into 293 cells using the calcium phosphate method. Purified viral plaques were screened initially by PCR and subsequently by -gal staining /assay ( see below ) to identify recombinant clones. Propagation and titer of recombinant adenoviruses was performed using standard methods. 22 Titers for these two viruses were obtained by serial dilution in parallel and repeated three times to ensure accuracy of experiments comparing the two in a head -to -head fashion. The absence of replication competent adenovirus was confirmed by negative plaque assays on HeLa and MCF -7 cells.
In vitro adenoviral infection
All in vitro infections with the exception of the thermotolerance experiment (see below ) were carried out as follows: cesium gradient purified recombinant adenovirus stock was diluted in a total volume of 500 L of serum -free -MEM /well. The diluted adenoviral stock was added directly to each well of a six -well dish containing the desired cell line in 2.5 mL of -MEM+ 10% FBS. This was incubated at 378C for 24 hours at which time the dishes were heated as described above. Adenovirus concentrations were adjusted to ensure 80± 90% infection of each cell type based on previously determined infection efficiency.
Thermotolerant cells were infected as follows. Thermotolerance was induced by an initial exposure to 438C for 30 minutes. At various time points thereafter, cells were reheated to 438C or control treated at 378C for 30 minutes. One hour before reheating, cells were infected with the specified amount of adenovirus diluted in 300 L of serumfree -MEM per well of a six -well dish at 378C. Immediately before reheating, the virus -containing medium was aspirated and replaced with fresh prewarmed media.
-Gal enzymatic activity and staining
To stain for -gal activity, cells were first washed three times with PBS -Ca ± Mg ( 150 mM NaCl, 15 mM Na phosphate, pH 7.3 ) then fixed with 2% formaldehyde, 0.2% glutaraldehyde in PBS -Ca ± Mg for 5 minutes at 48C. After fixation, cells were washed three times with PBS -Ca ± Mg ( +2 mM MgCl 2 , 0.02% NP -40), stained for 3 hours at 378C with a solution containing 1 mg /ml X -gal ( Sigma, St. Louis, MO ), 5 mM K 3 Fe( CN ) 6 , 5 mM K 4 Fe(CN ) 6 , 2 mM MgCl 2 , washed three times with PBS -Ca ± Mg , three times with water, and air dried. -Gal enzymatic activity was determined using the GalactoStar chemiluminescent -gal assay system (Tropix, Bedford, MA ) following the manufacturers directions for mammalian cells. Chemiluminescence was measured using a Berthold (Germany ) Lumat LB 9507 tube luminometer and quantitated against a -gal (Sigma) standard curve. Protein assays were carried out using the detergent compatible protein assay kit ( Bio -Rad, Mississauga, ON, Canada ) modified with iodoacetamide (Sigma ) to correct for the presence of DTT and detergent in the lysis buffer (as per Bio -Rad US / EG bulletin 1909 ). Activities are expressed as picograms -gal per microgram protein and are presented as the mean SD of at least three independent experiments. Statistical significance for comparisons between two measurements was determined by the unpaired two-tailed Student's t test. Values of P < .05 were considered significant.
HeLa cell / SCID mouse hyperthermia model
HeLa cells (5Â10 5 in 20 L -MEM+ 10% FBS total volume ) were injected subcutaneously (s.c. ) in the dorsum of a rear hind foot pads of SCID mice, in accordance with a protocol approved by the animal ethics committee at the Ontario Cancer Institute. Using this method, tumors form within 4± 6 weeks in approximately 75% of the animals. Once the tumors reached $125 mm 3 , they were injected with three single, intratumoral doses of 1Â10 8 pfu (in 10 L of 10 mM Tris pH 8.0) of Ad.70b.g on three successive days. Twenty -four hours following the last injection the mice were anaesthetized with Innuvar -Vet IP ( 0.08 mL of a 1:100 dilution ) and ketamine IM ( 0.08 mL of a 20 mg / mL stock ). Mice were immobilized in a Plexiglas chamber mounted on a pedestal in a calibrated Haake water bath. 23 The tumor-bearing foot was drawn through a precut hole in the chamber such that only the tumor-bearing foot was submerged at either 37 or 448C. The tumor was then treated for 30 minutes at the desired temperature. Rectal temperature was monitored throughout treatment. Twentyfour hours later, the mice were sacrificed, and the tumors and livers were immediately frozen in Tissue Tek O.T.C. compound ( VWR Can -Lab, Toronto, ON, Canada ) and stored at À 708C. Six serial sections ( 5 m ) were taken at each of five random levels throughout the tissues sampled. The sections were fixed and stained for -gal activity as described above. Sections were counterstained with Neutral Red (0.1% ), dried and examined by light microscopy.
RESULTS
Induction of -gal activity following heating of MCF -7 cells infected with Ad.70b.g. Recombinant adenoviruses con-taining either the wild -type hsp70b promoter (Ad.70b.g) or the HSE -modified promoter (Ad.HSE.70b.g ) were generated by homologous recombination between the shuttle vector and the pJM17 plasmid following cotransfection into 293 cells (Fig 1 ) . To examine the heat -responsiveness of gene expression from the Ad.70b.g construct, MCF -7 cells were infected with a multiplicity of infection ( MOI ) of 10 pfu /cell ( transduction efficiency of 80± 90% ) and -gal activity were assessed at various time points following heat treatment. Cells were heated at temperatures ranging from 40 to 458C for 30 minutes. As shown in Figure 2 , a temperaturedependent increase in -gal activity was observed for all treatment temperatures 418C. The maximum expression rate observed occurred between 0 and 3 hours postheating for temperatures in the 41± 448C range and between 3 and 6 hours posttreatment in cells heated to 458C. Fold induction of -gal activity reached near-maximal levels by 6 hours but peaked at 12 hours postheating for all groups tested. In the clinical target range of hyperthermic treatment ( 42± 448C), -gal activity was induced 10 -to 100-fold above basal levels. Induction was highest at 458C, reaching a maximum of $200 -fold over basal levels. A 2 -fold increase was observed following heating to 418C, and no induction was evident at 408C. These results demonstrate that the hsp70b promoter can provide high levels of induction of gene expression in MCF -7 cells in the target temperature range for clinical hyperthermia.
The addition of synthetic Heat Shock Elements can increase heat responsiveness in the clinical target temperature range
To determine whether the addition of synthetic HSE could increase the responsiveness of the hsp70b promoter to heat treatment, MCF -7 cells were infected with either Ad.70b.g or the modified Ad.HSE.70b.g vector and -gal activity was measured 24 hours postheating (40 to 458C for 30 minutes). Promoter activity, expressed as fold -induction relative to control values measured at 378C, is presented in Figure 3 . The addition of synthetic HSE sequences to the wild -type hsp70b promoter resulted in significant increases (P < .05) in the fold -induction of reporter gene expression levels in cells heated to 428C and above. The increase in -gal activity and fold -induction was particularly evident at higher temperatures, reaching levels that were up to 10 -fold higher than the maximum expression levels observed with the hsp70b promoter alone ( 200-vs. 2000 -fold basal expression at 458C). At 438C reporter gene expression from the HSE -modified promoter was 3.5-fold greater than the wild -type hsp70b promoter ( see also Fig 4) . These results demonstrate that the activity of the hsp70b promoter at clinically achievable temperatures can be enhanced by the addition of synthetic HSE. (Fig 4a) . The benefit provided by the additional HSE elements, expressed as an enhancement ratio ( Ad.HSE.70b.g induced -gal activity /Ad.70b.g induced -gal activity ), is presented in Figure 4b . Levels of heat induction from the modified hsp70b promoter were significantly (P < .05 ) greater than the wild -type promoter in five of the six cell lines studied, providing corroborative evidence that the addition of HSE elements can enhance the heat response over that seen with the hsp70b promoter alone. Collectively, the results presented in Figures 2± 4 suggest Ad.70b.g or Ad.HSE.70b.g 1 hour before reheating. At 8, 14, and 30 hours postinduction of thermotolerance, cells were reheated to 438C for 30 minutes to stimulate -gal expression, and -gal activity was measured 24 hours later as in previous experiments. Induction of thermotolerance had no effect on infectivity of MCF -7 cells at the MOI levels used for these experiments ( data not shown ). As shown in Figure 5 , levels of heat -inducible gene expression were decreased in thermotolerant cells compared to controltreated cells at all time points studied. However, thermotolerant cells infected with either Ad.70b.g or Ad.HSE.70b.g still expressed significant levels of -gal activity as early as 8 hours following the induction of thermotolerance, which increased over time as thermotolerance decayed. In addition, -gal gene expression levels from the Ad.HSE.70b.g vector were significantly ( P <.05) higher at all time points relative to Ad.70b.g. These observations are consistent with the activity of this vector in nonthermotolerant cells and further emphasize the enhanced activity of the modified promoter.
Heat -directed gene targeting of an adenoviral vector in a HeLa xenograft model
To examine whether this therapeutic strategy could be extended to a tumor model, HeLa cell tumors were grown s.c. in the hind limb footpads of SCID mice. The footpad Figure 6 . Heat -directed gene targeting to a xenograft tumor model. HeLa cell tumors were grown s.c. in the hind limb footpad of SCID mice. When a tumor volume of 125 mm 3 was reached, each tumor was injected with Ad.70b.g (1Â10 8 pfu ) once daily for 3 days. After 24 hours injected tumors were heated to either 37 or 448C for 30 minutes as described in Materials and Methods, and 24 hours later animals were sacrificed and tumors and livers removed, frozen, and sectioned. Individual sections were stained for -gal activity and counter -stained with Neutral Red. Representative sections are shown for tumors injected with Ad.70b.g and heated to 378C ( panels a and c ) or 448C ( panel b and d ). Panels c and d are higher magnifications of boxed areas indicated in panels a and b. Under these experimental conditions -gal staining was patchy and consistently represented 10 ± 15% of sections taken from tumors heated to 448C. Also shown is a mock -infected tumor heated to 448C ( panel e ) and a liver section from an animal injected with Ad.70b.g and heated to 448C ( panel f ). Bars = 100 m in panels a, b, e, and f; 20 m in panels c and d.
Cancer Gene Therapy, Vol 7, No 12, 2000 BRADE, NGO, SZMITKO, ET AL: HEAT-DIRECTED GENE TARGETING model for tumor growth was chosen because it provides a relatively straightforward model for tumor heating and the maximum intratumoral temperature that can be reached is well defined. Several human breast and cervical tumor cell lines were tested for both adenoviral infection efficiency and their growth characteristics in the footpad model. The HeLa cell line derived from a human adenocarcinoma of the cervix was chosen because of its high adenoviral transduction efficiency, ease of growth in the mouse footpad, and its wellcharacterized response to hyperthermia treatment. Furthermore, in vitro studies confirmed that HeLa cells infected with Ad.70b.g exhibit comparable kinetics, basal levels, and maximum heat -inducible levels of -gal gene expression to MCF -7 cells ( data not shown ). When the HeLa cell tumors reached 125 mm 3 , they were injected intratumorally with Ad.70b.g (1Â10 8 pfu per dayÂ3 days ). Twenty -four hours following the last injection, tumors were heated to either 37 or 448C for 30 minutes by water-bath immersion. A further 24 hours following heating, each mouse was sacrificed and its tumor and liver were removed for assessment. As shown in Figure 6 ( panels a and c), no appreciable -gal staining was observed in tumors treated at 378C. In contrast, patches of intense, nuclear-localized staining were observed in tumors heated to 448C at all levels sampled (panels b and d ), and staining patterns were consistent between serial sections. Under these experimental conditions 10± 15% of the total area of tumor sections stained positive for -gal expression. No evidence of -gal staining was observed in either mockinfected tumors ( panel e ) or in the livers (panel f) of either control or heat -treated mice. These results demonstrate the feasibility of heat -directed gene expression in an in vivo system.
DISCUSSION
Heat -inducible gene transfer vectors may allow therapeutic genes to be targeted to locally heated tumors, thereby reducing nonspecific systemic gene expression. Similarly, hyperthermic outcomes may be improved by expressing a transgene with a significant bystander effect to compensate for areas of the tumor that are under-heated due to vascular or technical factors. In a previous study, 16 heat -directed gene expression was demonstrated in prostate cancer cells heated to 418C in vitro. The goal of this study was to examine quantitatively several clinically relevant parameters of heatinducible gene expression using this type of vector. These included threshold of induction, basal level of expression, maximal induction levels, dose response to temperature, effect of thermotolerance, and the variability of heat induction among different tumor cell lines. Synthetic HSE sequences were added to the hsp70b promoter to assess whether these characteristics could be improved. In addition, we examined whether this approach can be used successfully in an in vivo setting.
Our data demonstrate that the hsp70b promoter can drive high -level transgene expression in the context of an adenoviral vector while maintaining relatively low levels of basal expression. Kinetic studies in MCF -7 cells following heat shock suggest that gene expression is activated within 30 minutes, peaks between 3 and 6 hours, and returns to baseline levels by 12 to 24 hours. This result is in keeping with previous studies 16, 24 and suggests that the hsp70b promoter functions normally within the context of the vector sequences.
High levels of induction were also observed in five other human breast cancer cell lines ranging from 90 -to 850 -fold above basal levels following treatment for 30 minutes at 438C. In an attempt to enhance this response further, a second adenovirus was constructed containing an additional synthetic HSE cassette upstream of the hsp70b promoter. This modification significantly increased the heat responsiveness of the promoter in five of the six cell lines tested. When tested in MCF -7 cells over a range of temperatures, significant increases in expression were apparent at 428C and above. These results raise the possibility that the hsp70b promoter can be further modified to decrease its activation threshold to lower temperatures. However, care must be taken to retain the minimal basal levels of activity found in all cell lines tested (ranging from one to four times background, data not shown ). This suggests that the hsp70b promoter (or a modified version of it ) can provide a relatively broad therapeutic index and may be useful for driving expression of highly toxic genes. Radiation responsive promoters have been used in an analogous manner to drive expression of tumor necrosis factor . This approach has yielded promising results using clinically relevant radiation dosing. 8, 25 At these dose levels, induction of gene expression is in the 2 -to 4 -fold range 7 further emphasizing the potential offered by heat -responsive promoters.
Both basal and maximal levels of gene expression, as well as the degree of enhancement conferred by the additional HSEs, displayed some intercell line variation. Similar differences in the response of the hsp70b promoter have been noted in other cell lines. 26, 27 Hsp70b promoter activation is highly dependent on HSE / HSF -1 and because activation of HSF -1 is highly regulated, there are many factors that could contribute to this variability. HSF -1 converts from a serine phosphorylated, inactive monomer to a hyperphosphorylated, activated trimer localized to discrete nuclear granules following disruption of protein homeostasis ( e.g., heat shock, amino acid analogues 13 ). This multistep process is regulated on several levels by various chaperones and regulatory factors, (e.g., Hsp90, Hsp70, Hdj -1, and HSBP-1; 28 ± 30 ) and through alterations in certain oncogenes and cell signaling pathways. For example, activation of the MAP kinase pathway has been shown to repress HSF -1 and the heat shock response. 31 ± 33 Frequently mutated tumorsuppressor genes such as p53 and WT1 can induce gene expression in an HSE dependent manner, although the mechanism underlying this process is not clear. 34, 35 It is therefore probable that the oncogenic profile of a tumor cell line can influence basal levels of hsp70 expression as well as fold induction following heat treatment. Although studies such as these illustrate the complexity of stress signaling through HSF -1 leading to HSE -dependent induction of gene expression, they also raise the possibility that heat -inducible promoters are amenable to manipulations that could improve their performance in gene therapy applications.
Induction of thermotolerance has a significant impact on clinical hyperthermia and treatments are generally given only once per week to allow for its decay. Understanding the impact of thermotolerance on gene therapy strategies involving hyperthermia is therefore, of critical importance. Hsp70a gene expression is attenuated under thermotolerance 36 and our data suggest that the hsp70b promoter is also less responsive to heat in thermotolerant cells. The addition of HSE sequences was also shown to result in enhanced gene expression under thermotolerant conditions suggesting that additional manipulation of the hsp70b promoter sequence may further improve therapeutic geneexpression levels in thermotolerant cells.
As with any novel approach to cancer therapy, clinical application of this strategy will require extensive preclinical testing in in vivo tumor models. Our results demonstrate that intratumoral administration of a heat -inducible adenoviral vector can induce gene expression following local tumor heating in a HeLa xenograft model. These results demonstrate that heat-directed gene therapy may be a feasible approach to targeting gene expression to locally heated tumors using clinical hyperthermia. The patchy distribution of gene expression can be attributed to nonuniform distribution of the recombinant adenovirus 37, 38 as well as inhomogeneous tumor heating. 23 In summary, we have demonstrated heat -targeted gene expression from two novel adenoviral vectors in vitro and in vivo. Low levels of basal expression were observed coupled with high levels of heat -induced expression. The observations were consistent in a variety of human breast cancer cell lines. Appending additional HSEs to the hsp70b promoter improved inducibility and response under both naive and thermotolerant conditions. Testing of one of the vectors in a human tumor xenograft model demonstrated proof of principle that heat can be used to target gene expression in vivo. Given the very low level of basal expression observed, one can envisage construction of viruses bearing highly toxic genes that could be targeted to tumors using currently available hyperthermia technology.
